BEAM has 36-month beta value of 1.95. Analysts have mixed views on the stock, with 9 analysts rating it as a “buy,” 4 as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for BEAM is 88.04M, and currently, short sellers hold a 11.35% ratio of that float. The average trading volume of BEAM on March 25, 2025 was 1.58M shares.
BEAM) stock’s latest price update
The stock of Beam Therapeutics Inc (NASDAQ: BEAM) has decreased by -4.04 when compared to last closing price of 24.01. Despite this, the company has experienced a 1.99% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2025-03-21 that Recently, BEAM reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. Unfortunately, they concurrently announced a $500 million equity offering, which may have caused concerns about near-term dilution. Still, BEAM-302 has innovative in vivo base editing technology that could potentially offer a one-time curative therapy for patients suffering from AATD.
BEAM’s Market Performance
Beam Therapeutics Inc (BEAM) has seen a 1.99% rise in stock performance for the week, with a -25.17% decline in the past month and a -14.19% plunge in the past quarter. The volatility ratio for the week is 5.92%, and the volatility levels for the past 30 days are at 8.90% for BEAM. The simple moving average for the past 20 days is -9.20% for BEAM’s stock, with a -10.69% simple moving average for the past 200 days.
Analysts’ Opinion of BEAM
Many brokerage firms have already submitted their reports for BEAM stocks, with Scotiabank repeating the rating for BEAM by listing it as a “Sector Outperform.” The predicted price for BEAM in the upcoming period, according to Scotiabank is $40 based on the research report published on March 10, 2025 of the current year 2025.
Leerink Partners gave a rating of “Outperform” to BEAM, setting the target price at $39 in the report published on November 06th of the previous year.
BEAM Trading at -13.32% from the 50-Day Moving Average
After a stumble in the market that brought BEAM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.64% of loss for the given period.
Volatility was left at 8.90%, however, over the last 30 days, the volatility rate increased by 5.92%, as shares sank -22.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.47% lower at present.
During the last 5 trading sessions, BEAM rose by +2.26%, which changed the moving average for the period of 200-days by -5.68% in comparison to the 20-day moving average, which settled at $25.38. In addition, Beam Therapeutics Inc saw -7.10% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BEAM starting from Cavanagh Bethany J, who sale 6,287 shares at the price of $35.00 back on Feb 18 ’25. After this action, Cavanagh Bethany J now owns 37,527 shares of Beam Therapeutics Inc, valued at $220,045 using the latest closing price.
Bellon Christine, the Chief Legal Officer of Beam Therapeutics Inc, sale 10,000 shares at $34.00 during a trade that took place back on Feb 14 ’25, which means that Bellon Christine is holding 102,968 shares at $340,000 based on the most recent closing price.
Stock Fundamentals for BEAM
Current profitability levels for the company are sitting at:
- -6.54 for the present operating margin
- 0.74 for the gross margin
The net margin for Beam Therapeutics Inc stands at -5.93. The total capital return value is set at -0.45. Equity return is now at value -43.94, with -29.39 for asset returns.
Based on Beam Therapeutics Inc (BEAM), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -2.15. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is -29.29.
Currently, EBITDA for the company is -415.57 million with net debt to EBITDA at 0.31. When we switch over and look at the enterprise to sales, we see a ratio of 34.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.82.
Conclusion
To put it simply, Beam Therapeutics Inc (BEAM) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
